메뉴 건너뛰기




Volumn 140, Issue 11, 2014, Pages 1947-1956

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

(26)  Pönisch, Wolfram a   Holzvogt, Bruno a   Plötze, Madlen a   Andrea, Marc a   Bourgeois, Malvina a   Heyn, Simone a   Zehrfeld, Thomas b   Hammerschmidt, Doreen c   Schwarz, Maik d   Edelmann, Thomas e   Becker, Cornelia d   Hoffmann, Franz Albert d   Schwarzer, Andreas d   Kreibich, Ute f   Gutsche, Kerstin g   Reifenrath, Kolja h   Winkelmann, Cornelia i   Krahl, Rainer a   Remane, Yvonne a   Hennig, Evelin a   more..


Author keywords

Bendamustine; Bortezomib; Newly diagnosed multiple myeloma; Prednisone

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; PREDNISONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CHLORMETHINE DERIVATIVE; PYRAZINE DERIVATIVE;

EID: 84916891869     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1737-9     Document Type: Article
Times cited : (27)

References (36)
  • 1
    • 0028775544 scopus 로고
    • The treatment of multiple myeloma
    • PID: 8289856, COI: 1:STN:280:DyaK2c7hvFWntA%3D%3D
    • Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330:484–489
    • (1994) N Engl J Med , vol.330 , pp. 484-489
    • Alexanian, R.1    Dimopoulos, M.2
  • 2
    • 0025294041 scopus 로고
    • Renal failure in multiple myeloma. Pathogenesis and prognostic implications
    • PID: 2383164, COI: 1:STN:280:DyaK3czktlGqsg%3D%3D
    • Alexanian R, Barlogie B, Dixon D (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150:1693–1695
    • (1990) Arch Intern Med , vol.150 , pp. 1693-1695
    • Alexanian, R.1    Barlogie, B.2    Dixon, D.3
  • 3
    • 84919469114 scopus 로고    scopus 로고
    • Bendamustine, bortezomib and dexamethasone (BBD) as first-line treatment of patients (pts) with multiple myeloma who are not candidates for high dose chemotherapy: toxicity comparison of two dose schedules
    • Berdeja JG, Savona MR, Chu L, Essell J, Murphy P, Bauer T, Raefsky E, Boccia RV, Flinn IW (2013) Bendamustine, bortezomib and dexamethasone (BBD) as first-line treatment of patients (pts) with multiple myeloma who are not candidates for high dose chemotherapy: toxicity comparison of two dose schedules. Blood (Abstract) 122:3193
    • (2013) Blood (Abstract) , vol.122 , pp. 3193
    • Berdeja, J.G.1    Savona, M.R.2    Chu, L.3    Essell, J.4    Murphy, P.5    Bauer, T.6    Raefsky, E.7    Boccia, R.V.8    Flinn, I.W.9
  • 5
    • 49449107318 scopus 로고    scopus 로고
    • Pathogenesis and treatment of renal failure in multiple myeloma
    • PID: 18528426, COI: 1:CAS:528:DC%2BD1cXpslSnur4%3D
    • Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485–1493
    • (2008) Leukemia , vol.22 , pp. 1485-1493
    • Dimopoulos, M.A.1    Kastritis, E.2    Rosinol, L.3    Blade, J.4    Ludwig, H.5
  • 6
    • 77449137146 scopus 로고    scopus 로고
    • Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib based regimes: identification of predictive factors
    • PID: 19717380, COI: 1:CAS:528:DC%2BD1MXhtF2qs73N
    • Dimopoulos MA, Roussou M, Gavriatopoulou M (2009a) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib based regimes: identification of predictive factors. Clin Lymphoma Myeloma 9:302–306
    • (2009) Clin Lymphoma Myeloma , vol.9 , pp. 302-306
    • Dimopoulos, M.A.1    Roussou, M.2    Gavriatopoulou, M.3
  • 9
    • 0016804136 scopus 로고
    • A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
    • PID: 1182674, COI: 1:STN:280:DyaE28%2FktFCqtA%3D%3D
    • Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854
    • (1975) Cancer , vol.36 , pp. 842-854
    • Durie, B.G.1    Salmon, S.E.2
  • 14
    • 0036340122 scopus 로고    scopus 로고
    • Metabolism and mechanisms of action of bendamustine: rationales for combination therapies
    • PID: 12170425, COI: 1:CAS:528:DC%2BD38Xmsl2is7g%3D
    • Gandhi V (2002) Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 29(Suppl. 13):4–11
    • (2002) Semin Oncol , vol.29 , pp. 4-11
    • Gandhi, V.1
  • 16
    • 34547706021 scopus 로고    scopus 로고
    • Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents
    • PID: 17488666, COI: 1:CAS:528:DC%2BD2sXhtFKrsrjN
    • Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA (2007) Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92:546–549
    • (2007) Haematologica , vol.92 , pp. 546-549
    • Kastritis, E.1    Anagnostopoulos, A.2    Roussou, M.3    Gika, D.4    Matsouka, C.5    Barmparousi, D.6    Grapsa, I.7    Psimenou, E.8    Bamias, A.9    Dimopoulos, M.A.10
  • 18
    • 25444512381 scopus 로고    scopus 로고
    • The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy
    • PID: 16154860, COI: 1:CAS:528:DC%2BD2MXhtFGrtLjN
    • Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H (2005) The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 90:1287–1288
    • (2005) Haematologica , vol.90 , pp. 1287-1288
    • Knop, S.1    Straka, C.2    Haen, M.3    Schwedes, R.4    Hebart, H.5    Einsele, H.6
  • 19
    • 84919481203 scopus 로고    scopus 로고
    • Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V
    • Krebs in Deutschland 2009/2010. 9. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Berlin (2013), 120–123
    • (2013) Berlin , pp. 120-123
  • 22
    • 0033574249 scopus 로고    scopus 로고
    • A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group
    • PID: 10075613, COI: 1:CAS:528:DyaK1MXitFChs7k%3D
    • Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470
    • (1999) Ann Intern Med , vol.130 , pp. 461-470
    • Levey, A.S.1    Bosch, J.P.2    Lewis, J.B.3    Greene, T.4    Rogers, N.5    Roth, D.6
  • 23
    • 84897849395 scopus 로고    scopus 로고
    • Bendamustine-Bortezomib-Dexamethasone (BBD) is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma
    • PID: 24227817, COI: 1:CAS:528:DC%2BC2cXjt1altL8%3D
    • Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weissmann A, Adam Z (2014) Bendamustine-Bortezomib-Dexamethasone (BBD) is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123:985–991
    • (2014) Blood , vol.123 , pp. 985-991
    • Ludwig, H.1    Kasparu, H.2    Leitgeb, C.3    Rauch, E.4    Linkesch, W.5    Zojer, N.6    Greil, R.7    Seebacher, A.8    Pour, L.9    Weissmann, A.10    Adam, Z.11
  • 31
    • 34347363426 scopus 로고    scopus 로고
    • Pharmacokinetics and toxicity profile of bendamustine in multiple myeloma patients with end-stage renal disease
    • Preiss R, Teichert J, Pönisch W, Niederwieser D, Matthias M, Merkle KH (2003) Pharmacokinetics and toxicity profile of bendamustine in multiple myeloma patients with end-stage renal disease. Hematolog J 4(Suppl. 1):263
    • (2003) Hematolog J , vol.4 , pp. 263
    • Preiss, R.1    Teichert, J.2    Pönisch, W.3    Niederwieser, D.4    Matthias, M.5    Merkle, K.H.6
  • 34
    • 84875840492 scopus 로고    scopus 로고
    • Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
    • Rummel, M.J., Niederle, N., Maschmeyer, G., Banat, G.A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., Kaiser, U., Weidmann, E., Dürk, H., Ballo, H., Stauch, M., Roller, F., Barth, J., Hoelzer, D., Hinke, A., Brugger, W.; Study group indolent Lymphomas (StiL)
    • Rummel, M.J., Niederle, N., Maschmeyer, G., Banat, G.A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., Kaiser, U., Weidmann, E., Dürk, H., Ballo, H., Stauch, M., Roller, F., Barth, J., Hoelzer, D., Hinke, A., Brugger, W.; Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210
    • (2013) Lancet , vol.381 , Issue.9873 , pp. 1203-1210


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.